Video

The role of doublet and triplet therapies in prostate cancer

Author(s):

Urology Times staff

“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.

In this video, William K. Oh, MD, discusses the rise of doublet and triplet therapies in the treatment of prostate cancer, and what questions are still being investigated related to these novel treatments.Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
AI-based tool aims to optimize MRI use in prostate cancer diagnosis
June 12th 2025

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

Madhur Nayan, MD, PhD
"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC
June 9th 2025

Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

Hannah Clarke
In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Amy L. Shaver, PhD, PharmD, MPH
June 5th 2025

GLP-1 agonist use is rising in men with prostate cancer

Benjamin P. Saylor
In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
Doctor giving a consultation to a patient and explaining medical informations and diagnosis | Image Credit: © Pcess609 - stock.adobe.com
June 4th 2025

ARANOTE: Darolutamide improves HRQoL in mHSPC

Benjamin P. Saylor
Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo
© 2025 MJH Life Sciences

All rights reserved.